Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of primary stenting
    		•  

    PRISAM (Kawashima) study, 1999

    Treatments

    Studied treatment Stent Palmaz-Schatz
    Control treatment
    Concomittant treatment No data
    Treatments description
    Crossover from Balloon Angioplasty to Stenting (%) 1  
    stent type Wiktor 

    Patients

    Baseline characteristics
    Age NA 
    male (%) NA 

    Method and design

    Randomized effectives 110 / 112 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 6 months


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    0 / 110
         1 / 112
         classic 0,20 [0,00;14,80]

    Revascularization

    25 / 110
         38 / 112
         0,67 [0,44;1,03]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Revascularization 25 / 110 (22,7%) 38 / 112 (33,9%) 0,67 [0,44;1,03]   7028 
    All cause death 0 / 110 (0,5%) 1 / 112 (0,9%) 0,51 [0,02;15,02]   7028 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:
  • 7028: Nordmann AJ, Bucher H, Hengstler P, Harr T, Young JPrimary stenting versus primary balloon angioplasty for treating acute myocardial infarction.Cochrane Database Syst Rev 2005;:CD005313

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Revascularization 22,73% 33,93% -112,0‰


    Reference(s)

    Trials register # NA
    • Kawashima A, Ueda K, Nishida Y, et al.ag. Quantitative angiographic analysis of restenosis of primary stenting using Wiktor stent for acute myocardial infarction: results from a multicenter randomized PRISAM study.6. Circulation. 1999;100(suppl 1):I–856..ag
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend